• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

The American College of Chest Physicians updates guidelines on PAH

Bioengineer by Bioengineer
February 8, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Glenview, Illinois – The American College of Chest Physicians® (CHEST) announced the publication of updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension (PAH). PAH is a progressive disease that affects the small arteries in the lungs, which can lead to right-sided heart failure and death. There is no cure for PAH; there are several medications approved for the treatment of the disease. In the latest evidence-based guideline, Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report, experts provide 78 evidence-based recommendations for appropriate use in treating patients with PAH.

“New recommendations and ungraded consensus-based statements were developed in this update based on new studies that were published since the 2014 guidelines. In addition, an evidence-based and consensus-driven treatment algorithm was created to guide the clinician through an organized approach to management,” says CHEST Pulmonary Arterial Hypertension Guidelines Committee Co-Chair, Dr. Deborah Jo Levine.

As part of the guideline development process, the panel updated the systematic review on the same clinical questions and criteria. Based on the results of the systematic review, the panel developed two new recommendations about pharmacologic therapy for PAH:

    * For treatment-naive patients with PAH who are World Health Organization (WHO) functional class II and III, we suggest initial combination therapy with ambrisentan and tadalafil to improve six-minute walk distance (6MWD).

    * For stable or symptomatic patients with PAH on background therapy with ambrisentan, we suggest the addition of tadalafil to improve 6MWD.

The complete guideline article is free to view in the Online First section of the journal CHEST®.

###

About CHEST Guidelines

Guidelines include systematically developed, evidence-based and periodically updated recommendations for the prevention, diagnosis and management of medical conditions. These guidelines are intended to inform health-care providers, patients and policy makers in making informed clinical decisions.

About the American College of Chest Physicians®

CHEST is the global leader in the prevention, diagnosis and treatment of chest diseases. Its mission is to champion advanced clinical practice, education, communication and research in chest medicine. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For information about the American College of Chest Physicians and its flagship journal CHEST®, visit chestnet.org.

Media Contact
Andrea Camino
[email protected]
224-521-9513

Related Journal Article

http://www.chestnet.org/News/Press-Releases/2019/02/PAH-guidelines
http://dx.doi.org/10.1016/j.chest.2018.11.030

Tags: CardiologyCritical Care/Emergency MedicineInternal MedicineMedicine/HealthPulmonary/Respiratory Medicine
Share12Tweet7Share2ShareShareShare1

Related Posts

Predicting Lung Infections After Brain Hemorrhage

Predicting Lung Infections After Brain Hemorrhage

August 2, 2025
blank

Impact of Morphology and Location on Aneurysms

August 2, 2025

Unraveling EMT’s Role in Colorectal Cancer Spread

August 2, 2025

Gut γδ T17 Cells Drive Brain Inflammation via STING

August 2, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    40 shares
    Share 16 Tweet 10
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Predicting Lung Infections After Brain Hemorrhage

Impact of Morphology and Location on Aneurysms

Unraveling EMT’s Role in Colorectal Cancer Spread

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.